Critical Pharmaceuticals United Kingdom

Critical Pharmaceuticals is a privately funded clinical stage biotechnology company focused on developing improved versions of marketed biologic drugs using it’s patented drug delivery platform technologies.

The company’s lead products are an intranasal human growth hormone product, targeted at a $3.1bn market, and CP046 intranasal teriparatide product for the treatment of osteoporosis, a $1.2bn market. The development pathway for both programs is clear and low risk as it involves drugs with well established efficacy and toxicity, and previous exposure to man in a successful Phase I clinical trials.

Critical Pharmaceuticals patented CriticalMix™ and CriticalSorb™ technology platforms are applicable to the large and fast growing market of biological drugs. The technology has been validated in collaboration with other biopharmaceutical companies with two partner programs poised to enter clinical development.

The products and platform technology has extensive IP protection, including granted US patents.

Organisation type
Membership affiliation
Dr Gareth King
CEO 

Datatrial United Kingdom

Datatrial is a clinical technology organisation with supporting biometrics services. Our innovative nowEDC™ solution provides data capture, verification and validation, query management, data extract, randomization and real-time reporting in one integrated system. nowEDC is easy-to-use and is highly configurable, making it a natural fit for complex workflows and trial designs.

Organisation type
Keywords
CRO
Membership affiliation
Dr Emma Banks
LinkedIn logo CEO 
Miss Amy  Wright
Miss Amy Wright
LinkedIn logo Business Development Associate 

Ex Scientia United Kingdom

Based on the ground breaking Nature publication ‘Automated design of ligands to polypharmacological profiles’ and with several commercial collaborations underway ex scientia is the first company to develop a systematic approach to tailoring drugs against polypharmacology profiles for superior clinical efficacy. We are exploiting our advanced technologies to develop compounds with tailored selectivity and in particular a portfolio of efficacious bispecific drugs.

Our bispecific design technology delivers efficacious small molecule drugs binding novel target combinations, either within or between gene families. By hitting multiple nodes in the cellular network simultaneously better clinical efficacy can be achieved.

Non-specific, promiscuous interactions with undesired proteins frequently cause drug toxicity and adverse effects. Our tailored selectivity technology can be applied to the discovery of drug candidates with desired selectivity, thereby reducing side effects and toxicity.

Advances in phenotypic screening are opening new ways to deliver improved medicines. Our phenotypic design technologies can generate and optimise effective molecules using high content phenotypic data without prior consideration of the targets. 

Organisation type
Keywords
Biotechnology, Therapeutics, Small Molecules, Early Stage Drug Discovery.
Membership affiliation
Professor Andrew Hopkins
Professor Andrew Hopkins
CEO 
Dr Mark Swindells
Dr Mark Swindells
Chief Operating Officer 
Dr Denise Barrault
Dr Denise Barrault
Chief Commercial Officer 
Adam Michael

Glythera United Kingdom

Glythera Limited is a biotechnology company specializing in the development of platform technologies for next generation biotherapeutics. We have 2 core programmes:

- PermaLink™ - a novel, stable, highly cysteine-specific conjugation platform for antibody drug conjugates (ADCs)

PermaLink™ is associated with enhanced anti-tumour activity in vivo vs maleimide in comparative ADC models. It is suitable for cleavable and non-cleavable systems  

- PermaCarb™ - a novel sialylation correction platform which can (i) improve bioavailability & enhance product performance and (ii) remove the issue of sialic acid contamination. It is particularly appropriate for the development of biobetters and biosimilars   

PermaCarb™ has been validated vs several biotherapeutics, including FSH and etanercept 

Based in the NE of England, Glythera has dedicated bioprocessing and chemistry laboratories enabling us to conduct in-house evaluations for our partners  to progress applications of PermaLink™ and PermaCarb™ technologies. 

We are seeking license collaborations for PermaLink™ and out-license partners for PermaCarb™ 

Website:
www.glythera.com
Organisation type
Keywords
Biotech
Membership affiliation
Dr Ian Evetts
Dr Ian Evetts
LinkedIn logo Commercial Director 
Dr Dave Simpson
Dr Dave Simpson
LinkedIn logo CEO 

KWS BioTest Ltd. United Kingdom

KWS BioTest is an established contract research organization providing a wide range of drug discovery services spanning preclinical development from early cell biology, through efficacy models to clinical sample analysis.

KWS BioTest provides clients with a powerful combination of world-leading scientific expertise coupled with the latest methods and technologies to ensure the highest levels of quality and service at all times.  We specialise in the areas of immunology, inflammation and infection and work closely with our clients in the testing of their novel small molecules, biologics and ADCs as treatments for human disease, including specific experience across global vaccine development initiatives.  We can generate data to support all stages of compound and molecule development to maximise the chance of successful progression to each important project milestone. 

Our dedicated solutions for our clients often feature bespoke study designs, allowing them to benefit from our extensive experience across both therapeutic areas and molecule classes. Our team of expert scientists can provide support for both individual studies and as part of larger projects as a virtual extension of our clients’ laboratory capabilities.  We can assist in the interpretation of complex programs of work in target validation, lead optimisation, candidate selection, discovery support and clinical sample analysis, increasing the chance of molecules succeeding and helping bring them to the clinic faster.

Organisation type
Keywords
CRO
Membership affiliation
Mr Simon Johns
Head of Business Development 

Novozymes Biopharma UK United Kingdom

Novozymes Biopharma develops and manufactures sustainable, safe, biological based ingredients and technologies to provide pharmaceutical and medical device manufacturers the knowledge-based solutions needed to address the challenges in developing innovative, safer, and more consistent final products. The company's large-scale manufacturing facilities worldwide are run to cGMP Q7 quality standards to ensure that customers receive the highest level of product quality and consistency, as well as the security of long-term supply. Novozymes’ customer-integrated approach combines the company’s scientific know-how and the specific needs of customers to deliver improved products and performance. By combining Novozymes’ unique knowledge around our biological solutions such as recombinant albuminhalf-life extension and hyaluronic acid with the specific application knowledge of our customers, we work with companies to deliver improved performance and safety for next generation of medical device and pharmaceutical products.

Organisation type
Keywords
drug delivery
Membership affiliation
Dr Dave Mead
LinkedIn logo Business Development Director 
Ms Ann Gidner
LinkedIn logo Sales & BD Manager 

One Nucleus United Kingdom

About One Nucleus

Established in May 2010, One Nucleus is the result of the merger of ERBI and London Biotechnology Network. One Nucleus is a not-for-profit membership organisation for international life science and healthcare companies and the largest of its kind in Europe. The company is based in Cambridge UK and London, at the heart of Europe's largest cluster. The 470 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial Service Providers.

Organisation type
Keywords
Life science, membership, commercial, Service, Providers
Membership affiliation
Mr Tony Jones
Director, Business Development 

Phynova Group United Kingdom

Phynova is an innovative life sciences company based in Oxford with research facilities in China that uses a plant chemistry platform to develop patented actives for use in pharmaceuticals, nutraceuticals, and personal care products. Drug candidates and functional ingredients under development target joint pain and inflammation, post-operative ileus (POI), MRSA, hepatitis C, glucose control and hyperpigmentation and melanin production.

Source: Partnering360 (29/10/2014)

Website:
www.phynova.com
Organisation type
Keywords
Ltd
Membership affiliation
Mr Ian Scoular
Director of Business Development 
Mr Robert Miller
CEO 

Providion Ltd United Kingdom

As the world’s largest independent provider of innovative maintenance and support solutions for LC-MS and GC-MS instruments, Providion specialise in servicing Waters, Micromass, AB Sciex, Agilent & Thermo equipment for the drug discovery and manufacturing, biotechnology, food and environmental safety, and clinical research sectors.

Our team of product experts deliver everything from preventative maintenance visits to full service contracts. With comprehensive pre-owned instrument packages, free technical support, quality spare parts and rapid response to instrument breakdowns, we are proud to support over 450 satisfied customers worldwide!

Organisation type
Keywords
mass spectrometer, MS repair, instrument sales
Membership affiliation
Mrs Joanne Idowu
MD 
Mrs sarah schofield lord
Operations Manager 

Quay Pharmaceuticals United Kingdom

Quay Pharmaceuticals is experienced in providing a comprehensive out-sourcing service for formulation and analytical development with subsequent clinical trials manufacturing for pharmaceutical and biotechnology companies world-wide.

Working as a dedicated, pro-active part of your team we apply strong project management and technical expertise to take products quickly and cost effectively from late stage pre clinical through to the end of phase II clinical trials.

Quay Pharma has vast expertise in dosage form design and development and with Professor Mike Rubinstein (CEO) and Professor John Collett (CSO), Quay Pharma has built a reputation for specialising in the formulation of API’s that exhibit poor solubility and bio-availability and those which require modified or controlled release. This has resulted in many Quay Pharma clients successfully licensing products on to large, global pharmaceutical companies.

From MHRA licensed and FDA registered facilities the company provides;

•             pre-clinical to commercial formulation development

•             novel drug delivery system design

•             analytical – transfer or method development and validation

•             ICH stability testing

•             clinical trial manufacture in class 100,000 (ISO 8) environment

o             conventional, coated and controlled release tablets and capsules

o             powder, liquid / semi-solid fill capsules

o             liquid /semi solid formulations (e.g. nasal and oral solutions, creams)

o             pellets / spheroids and extrudates

o             medical devices

•             packing and labelling

•             full QC testing services

•             QP certification and importation of investigational medicinal products from outside the EU.

•             CMC’s and regulatory document support for product registration

Quay Pharma holds a Manufacturing Authorisation from the MHRA for the manufacture and testing of investigational medicinal products (IMP’s), as specified by the EU Clinical Trials Directive (2001/20/EC) and also possesses a “Specials” licence.

For further information contact:

Michael Kruidenier

European Business Development Manager

Telephone: +44 (0) 1244 837 004

Email: m.kruidenier@quaypharma.com

Organisation type
Keywords
CDMO
Membership affiliation
Mr Michael Kruidenier
LinkedIn logo European Business Development Manager 
Miss Maireadh Pedersen
LinkedIn logo CEO